Search Results
Jul 28, 2026, 06:00 ET Great Hearts Arizona Class of 2026 Earns $53.8 Million in Merit Scholarships, Achieves Top Academic Results
highest-performing public-school systems.About Great HeartsGreat Hearts is a nonprofit and the nation's largest provider of classical PK–12 education, serving more than 30,000 students across 52 brick‑and‑mortar academies in Arizona, Texas, and Louisiana, along with a national online academy.
More news about: Great Hearts Arizona
Jul 27, 2026, 09:12 ET DifGen Pharmaceuticals Receives FDA Clearance to Begin Clinical Development for a Single Injection treatment for Advanced Breast Cancer DFGN-101
position was supported by the company's Chemistry, Manufacturing and Controls (CMC) data package and by results from a pilot pharmacokinetic study showing a PK profile comparable to that of the reference product.The clearance reflects DifGen's formulation and clinical development capabilities and its
More news about: DifGen Pharmaceuticals LLC
Jul 25, 2026, 15:36 ET TTW Releases the Top 50 Beach Travel Destinations in the World for 2026
Pacific escape with luxury resorts, exceptional diving and authentic island culture.French Polynesia's Top 10 BeachesPK 9 Beach, Fakarava – White sand, coral atollMatira Beach, Bora Bora – Powder sand, turquoise lagoonTemae Beach, Moorea –
More news about: Travel And Tour World
Jul 22, 2026, 09:16 ET HKEY-AI4AI-Atlas™ 1.0: HKeyBio Uses AI to Curate Autoimmune Model Datasets
retrieval to organize HKeyBio's accumulated experience in autoimmune and allergic disease models, in vivo pharmacodynamics, pathology, immune endpoints, PK/PD, NHP responses and translational endpoints. HKEY-AI4AI-Atlas™ 1.0 at a GlanceWhat it is: HKEY-AI4AI-Atlas™ 1.0 is HKeyBio's
More news about: HKeyBio
Jul 20, 2026, 09:00 ET Argo Biopharma Doses First Participant in Phase I Clinical Trial of Factor XI Targeting siRNA Therapy BW-41012
is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous administration of BW-41012 in healthy volunteers in Australia. The study will assess safety and biomarkers
More news about: Argo Biopharmaceutical Co., Ltd
Jul 16, 2026, 15:34 ET Teaching Strategies Earns Two CODiE Awards for Innovation in Early Childhood Education
Teaching Strategies received the following honors:Best PK/Early Childhood Learning Solution for
More news about: Teaching Strategies
Jul 15, 2026, 08:15 ET Good News, Virginia: IXL Launches State-Specific Edition of LevelUp Diagnostic
IXLCurrently used by 18 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a state-of-the-art assessment suite. Available in more than 120 languages, IXL's end-to-end
More news about: IXL Learning
Jul 14, 2026, 09:00 ET Inductive Bio Wins 3rd Consecutive AI Drug Discovery Benchmark
to make higher-quality decisions consistently throughout discovery. Inside these virtual labs, AI chemistry assistants work with predictive ADMET and PK models to help scientists evaluate more hypotheses in silico and surface key risks earlier. The most promising molecules move from the virtual lab to
More news about: Inductive Bio, Inc.
Jul 14, 2026, 08:30 ET Use Novel ADME Tools to Improve Early Human PK Projection, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how integrated ADME tools and AI-driven human pharmacokinetic projection can help bring human PK insight earlier into drug discovery. The featured speakers will discuss how Tier 1 ADME profiling, automated data generation and integrated compound management can support
More news about: Xtalks
Jul 14, 2026, 06:00 ET Great Hearts Arizona Class of 2026 Earns $53.8 Million in Merit Scholarships, Achieves Top Academic Results
highest-performing public-school systems.About Great HeartsGreat Hearts is a nonprofit and the nation's largest provider of classical PK–12 education, serving more than 30,000 students across 52 brick and mortar academies in Arizona, Texas, and Louisiana, along with a national online academy.
More news about: Great Hearts Arizona
Jul 14, 2026, 00:01 ET PointsKash Completes Strategic Acquisition of ChainBytes Software Assets and Adds Founder Eric Grill to Accelerate AI-Powered Fintech Platform
beginning in 2027, supporting future enhancements across its cryptocurrency platform, KashPoint™ self-service financial centers, PK Pay™ digital banking platform, enterprise merchant solutions, and emerging artificial intelligence initiatives.Beyond the ChainBytes integration,
More news about: PointsKash Inc.
Jul 13, 2026, 12:00 ET Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
development plan remain essential to deal execution.Deals often stall due to weak biological rationale, unclear patient or biomarker strategies, poor PK/PD or therapeutic windows, and inadequate global development planning.The second panel was moderated by Kenneth C. Chen, Senior Director
More news about: ACROBiosystems
Jul 13, 2026, 09:16 ET HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence
answer first.3. Bridging endpoint designConnects pharmacodynamic endpoints, mechanism endpoints, translational biomarkers, PK exposure, PK/PD correlation and basic safety observations.HKeyBio integrates disease models, NHP research and translational reportingDeliverables
More news about: HKeyBio
Jul 13, 2026, 06:59 ET Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
intervention, with the majority resolving within a day.Bempikibart demonstrated a favorable pharmacokinetic (PK), pharmacodynamic and anti-drug antibody (ADA) profile in Part B. PK data from Part B support the loading dose regimen had its intended effect, achieving steady state concentrations approximately
More news about: Q32 Bio
Jul 13, 2026, 00:08 ET New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
#1-32-FRS-C). The session highlighted findings from the lecanemab SC-AI development program in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience data.Results showed that once-weekly 500 mg SC-AI achieved
More news about: BioArctic
Jul 13, 2026, 00:02 ET New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
#1-32-FRS-C). The session highlighted findings from the lecanemab SC-AI development program in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience data.Results showed that once-weekly 500 mg SC-AI achieved
More news about: BioArctic
Jul 12, 2026, 11:15 ET LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
FindingsThis session presented data from the lecanemab SC-AI development program in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience findings. Results showed that once-weekly 500 mg SC-AI achieved
More news about: Eisai Inc.
Jul 11, 2026, 08:05 ET Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
A, et al. Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2026. July
More news about: Novo Nordisk
Jul 11, 2026, 08:05 ET Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
A, et al. Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2026. July
More news about: Novo Nordisk
Jul 09, 2026, 08:31 ET MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation
More news about: MetaVia Inc.
Jul 08, 2026, 12:00 ET On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
vehicle for long-term value creation, not a mere transaction; deals often fail due to weak biology-disease links, poor biomarker strategies, or suboptimal PK/PD profiles. Crucially, MNCs now view China as a core innovation fountain, not a cost-driven market. To succeed, Chinese biotechs must provide globally
More news about: bioSeedin
Jul 08, 2026, 07:00 ET BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
progressive GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in
More news about: BioLineRx Ltd.; Hemispherian AS
Jul 03, 2026, 13:55 ET Xtalks Announces its Life Science Webinar Calendar for July 2026
RiskJul 29 - Streamline Targeted LNP Development to Improve Preclinical TranslationJul 30 - Use Novel ADME Tools to Improve Early Human PK ProjectionABOUT XTALKSXtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and
More news about: Xtalks
Jul 01, 2026, 10:46 ET Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight
xenograft, syngeneic, patient-derived xenograft (PDX), and genetically engineered mouse models (GEMMs), as well as pharmacokinetic/pharmacodynamic (PK/PD), biomarker, toxicology, and mechanism-of-action studies. By leveraging validated tumor models and advanced imaging and analytical capabilities, oncology-based
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 07:00 ET Avista Healthcare Partners Acquires Sanotact Group GmbH
experience and track record in consumer healthcare and the wider consumer space. This includes: Cooper Consumer Health, Vision Healthcare, Omega Pharma, TOCG, PK Consumer Health and Fagron amongst others. For more information, visit
More news about: Avista Healthcare Partners